Cell and Gene Therapy Ocular Services
Optimized Ocular Models Focused on Improving Outcomes Absorption Systems offers specialized preclinical in vivo ocular models for cell and gene therapy products. Wild type, genetically modified, immunodeficient, and disease-induced models are available, and all animals are pre-screened for ophthalmic abnormalities. From proof of concept to IND-enabling studies, we provide consultative design based on species-specific physiology and compatibility with your product and delivery procedure.
- Wet AMD
-VEGF Induced Vascular Leakage
-Laser Choroidal Neovascularization (CNV) - Glaucoma
- Corneal Wound Healing
- Keratoconjunctivitis Sicca (KCS)
- Uveitis
- Allergic Conjunctivitis
- Diabetic Retinopathy
- Bacterial Keratitis
- Viral Conjunctivitis
- Corneal Neovascularization
- New Model Development
| Mouse | Dog | Rabbit |
| Pig | Minipig | Sheep |
State-of-the-art equipment to capture data and images:
- Direct & Indirect Ophthalmoscopy
- Slit-Lamp Biomicroscopy
- Optical Coherence Tomography (OCT)
– Posterior Segment: 30° Lens, 55° Lens
– Anterior Segment: Cornea Lens - Fundus Photography
- Fluorescein Angiography
- Auto-Fluorescence
- Indocyanine Green (ICG)
- Pachymetry
- Intraocular Pressure (IOP)
- Electroretinography (ERG, mfERG)
- Visual Evoked Potential (VEP)
- Specular Microscopy
- Ultrasound
- Phacoemulsification
- Vitrectomy
Dose Routes
| Topical | Punctal |
| Intracorneal | Subconjunctival |
| Intravitreal | Subtenon |
| Intracameral | Suprachoroidal |
| Periocular | Subretinal |
Tissue Dissection
|
|
Our experts have worked with the leading makers of ophthalmic drugs, devices and cell and gene therapies. We can guide you through customized study endpoints based on the intended route of administration and clinical indication. Typical endpoints include:
- Proof of Concept
- Toxicology (Local and Systemic)
- Biodistribution
- Shedding
- Immunogenicity
- Protein Expression
- Biological Activity
